טוען...
Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report
Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allo...
שמור ב:
| הוצא לאור ב: | Gynecol Oncol Rep |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6374783/ https://ncbi.nlm.nih.gov/pubmed/30809568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2019.01.007 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|